Leading Technology Group is an investment company with a primary focus on service and technology businesses in the fields of life sciences and health.  We are actively seeking opportunities to buy or build high quality niche businesses that have the potential to grow organically.

LTG Advisory Board


Professor Gwendalyn Randolph – Advisor, Atherosclerosis


Professor Gwendalyn Randolph

Gwendalyn is Professor of Pathology and Immunology and Head of the Division of Immunobiology at Washington University School of Medicine in St Louis. Her laboratory’s research integrates the study monocytes, macrophages, and dendritic cells with vascular and lymphatic biology. This emphasis includes the development of pioneering assays to study the trafficking of immune cells and lipoproteins in atherosclerosis.

Professor Len Kritharides – Advisor, Cardiology and Atherosclerosis


Professor Len Kritharides

Len is the Head of Department of Cardiology and Director of Echocardiography at Concord Repatriation Hospital and Professor Medicine at the University of Sydney. He is also Group Head of the Atherosclerosis Laboratory at the ANZAC Research Institute and a board member of the Heart Research Institute. In addition to his role as a General and Interventional Cardiologist, Len undertakes a wide range of clinical and basic research.

Dr. Anthony (Tony) Johns – LTG Lead Researcher, Atherosclerosis


Dr. Tony Johns

Tony has over 30 years of experience in the pharmaceutical industry, where he was responsible for supervising both basic and clinical research. At Schering AG (Berlex) he was Section Head of Vascular Biology and at Bayer, Director of Clinical Affairs for CardioAspirin where he designed and initiated the ARRIVE trial (12,000 patients followed for 5-7 years in 7 countries). He has authored and published numerous papers, reviews and book chapters in Pharmacology, Biochemical Pharmacology and Molecular Pharmacology.


© 2020 Leading Technology Group